SOHO 2020 | Spleen volume responses in fedratinib treated myelofibrosis patients
Ruben Mesa
Ruben Mesa, MD, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, outlines the spleen volume responses as assessed in the JAKARTA study (NCT01437787), where patients with myelofibrosis were treated with fedratinib, a JAK inhibitor. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
Related videos
1:38 The search for better post-MPN AML treatment: decitabine and ruxolitinib
Farhad Ravandi
3:42 Novel approaches to PV and ET
Alessandro Lucchesi
5:06 New insights in the biology of myeloproliferative neoplasms
Anna Rita Migliaccio
3:19 Finding novel targets for myelofibrosis from animal models
Anna Rita Migliaccio
1:39 Next questions in the treatment and management of MPNs
Srdan Verstovsek
